Figure 2: Therapeutic efficacy of mAbm336 in protecting Tg mice against lethal MERS-CoV challenge.

Tg mice were treated (i.p.) with human m336 antibody 12 h after infection (i.n) with 104 TCID50 of MERS-CoV. An irrelevant mAb, m102.4, was also included as the control. Challenged mice were monitored daily for the weight loss (A) and accumulated mortality (B), expressed as percent (%) weight loss and survival, respectively.